Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +190,916.81%
#2 Beta Finance Beta Finance +8,977.34%
#3 Velas Velas +461.19%
#4 Tribe Tribe +73.83%
#5 Orochi Network Orochi Network +51.29%
#6 Chainbase Chainbase +40.86%
#7 BabyBoomToken BabyBoomToken +34.51%
#8 Freysa AI Freysa AI +33.79%
#9 Block Street Block Street +28.93%
#10 Chrema Coin Chrema Coin +27.48%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rangering i aksjer #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aksjekurs
$0.00244926
Markedsverdi
$51.67K
Endring (1 dag)
5.88%
Endring (1 år)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Kategori

Healthcare
Antall utestående aksjer for Nuformix plc (NFX)
Antall utestående aksjer per September 2025: 2.03B
Ifølge Nuformix plc sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 2.03B. Ved slutten av September 2024 hadde selskapet 787.01M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Nuformix plc (NFX) fra 2014 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 2.03B 22.35%
2025 1.66B 111.05%
2024 787.01M 9.39%
2023 719.46M 20.22%
2022 598.45M 3.07%
2021 580.63M 21.71%
2020 477.06M 3.54%
2019 460.75M 23.34%
2018 373.55M 290.13%
2017 95.75M 59.34%
2016 60.09M 0.00%
2014 0.00 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 118.85%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -87.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -94.94%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -90.65%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M -76.21%
AU